Clinical trials: Cardiomyopathy, Dilated
Heart Failure, Dilated Cardiomyopathy
A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
AUGMENT-HF II is a study to evaluate the efficacy and safety of the Algisyl device. The purpose of this study is to investigate Algisyl employed as a method of left ventricular augmentation and restoration in patients with…
- Conditions
- Heart Failure, Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction
- Trial name
- AUGMENT-HFII (NCT03082508)
- Testing
- Algisyl, Standard Medical Therapy
- Volunteers
- 240 people
- Sponsor
- LoneStar Heart, Inc.
Dilated Cardiomyopathy
ACC - Atrial Contribution to CRT
This prospective study will evaluate in patients, fulfilling implant criteria for Cardiac Resynchronisation Therapy (CRT) implant, the optimal atrial contribution to the resynchronised ventricles in the event of right atrial…
- Trial name
- NCT00180323
- Testing
- Renewal
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
- Trial name
- NCT03447990
- Testing
- MYK-491
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Diseases, Congestive Heart Failure
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
Heart failure is the primary cause of morbidity and mortality worldwide. Currently drug treatments for heart failure manage the symptoms, but not restore the loss cardiomyocytes due to the very limited regenerative capability in…
- Conditions
- Cardiovascular Diseases, Congestive Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT04982081
- Testing
- hiPSC-CM therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Dilated Cardiomyopathy (DCM), Cardiovascular Diseases
BAG3-DCM Natural History Study
The goal of this international observational study is to learn about the natural history of Dilated Cardiomyopathy (DCM) arising from pathogenic BAG3 variants in adult patients ≥18 years of age.
- Conditions
- Dilated Cardiomyopathy (DCM), Cardiovascular Diseases, Heart Diseases, Genetic Diseases
- Trial name
- NCT07486752
- Volunteers
- 30 people
- Sponsor
- Rocket Pharmaceuticals Inc.
COVID19
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Trial name
- NCT05175690
- Testing
- Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Symptomatic Genetic Dilated Cardiomyopathy
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM).
- Trial name
- KINSHIP-DCM (NCT07210723)
- Testing
- danicamtiv
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
LMNA-Related Dilated Cardiomyopathy
A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated…
- Trial name
- NCT02351856
- Testing
- ARRY-371797, p38 inhibitor, oral
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Cardiomyopathy
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality…
- Trial name
- MyCLIMB (NCT05112237)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Tenaya Therapeutics
Pulmonary Arterial Hypertension, Dilated Cardiomyopathy
IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy
IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension, Dilated Cardiomyopathy, Congenital Heart Disease
- Trial name
- HEARTFUL-CHD (NCT06072937)
- Testing
- IntelliStent
- Volunteers
- 10 people
- Sponsor
- HeartPoint Global
Heart Failure, Cardiomyopathy, Dilated
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
This is a non-randomized, prospective, multi-center Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation.
- Trial name
- CorCinch-PMVI (NCT03560167)
- Testing
- AccuCinch® Ventricular Restoration System
- Where
- 19 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ancora Heart, Inc.
LMNA-Related Dilated Cardiomyopathy
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
This study is designed to evaluate the safety and tolerability of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The study will also assess exploratory measures of efficacy.
- Trial name
- NCT07606274
- Testing
- NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Nuevocor Pte. Ltd.
Heart Failure, Cardiomyopathy
An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001
The objective of this extension study is to evaluate the safety and potential beneficial effects of the Algisyl-LVR™ device in patients with established heart failure secondary to a dilated cardiomyopathy.
- Conditions
- Heart Failure, Cardiomyopathy, Dilated Cardiomyopathy
- Trial name
- NCT02226679
- Testing
- Algisyl-LVR
- Where
- 2 sites in Italy, Romania
- Volunteers
- 24 people
- Sponsor
- LoneStar Heart, Inc.
Heart Failure, Cardiomyopathy, Dilated
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
- Trial name
- CorCinch-HFrEF (NCT03533517)
- Testing
- AccuCinch® Ventricular Restoration
- Where
- 18 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ancora Heart, Inc.
Cardiovascular Disease (CVD), Heart Failure
Study of the Progression of Chronic Cardiovascular Conditions
This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.
- Conditions
- Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease
- Trial name
- OCORO (NCT07420907)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Prolaio
Symptomatic Genetic Dilated Cardiomyopathy (DCM)
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used…
- Trial name
- KINSHIP-OLE (NCT07771465)
- Testing
- Danicamtiv
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
Cardiomyopathy, Dilated
Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)
The purpose of this study is to evaluate the clinical safety and feasibility of Mysorba in patients with chronic non-ischemic dilated cardiomyopathy (DCM).
- Trial name
- NCT01478087
- Testing
- Mysorba
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Asahi Kasei Medical Co., Ltd.
Heart Failure, Dilated Cardiomyopathy
Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril
Paediatric long-term safety follow-up clinical trial in maximum 100 children with heart failure due to dilated cardiomyopathy or congenital heart disease, from 1 day to less than 12 years of age at recruitment into the preceding…
- Conditions
- Heart Failure, Dilated Cardiomyopathy, Congenital Heart Disease
- Trial name
- LENA-WP10 (NCT02654678)
- Testing
- Enalapril Orodispersible Minitablet
- Where
- 6 sites in Austria, Hungary and 3 more
- Volunteers
- 100 people
- Sponsor
- Ethicare GmbH
Heart Failure, Cardiomyopathies
Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study
This is prospective, non-randomized, single-arm, international, multicenter, clinical safety and performance clinical investigation to evaluate the AccuCinch® Ventricular Repair System for the treatment of heart failure, with or…
- Trial name
- NCT03183895
- Testing
- Left ventricular restoration
- Where
- 19 sites in Belarus, Belgium and 8 more
- Volunteers
- 132 people
- Sponsor
- Ancora Heart, Inc.
Cardiomyopathy, Dilated
Pilot Study of COR-1 in Heart Failure
The purpose of this study is to investigate the effect of COR-1 in combination with standard therapy in patients with heart failure. The safety and tolerability of COR-1 will also be assessed.
- Trial name
- NCT01391507
- Testing
- 0.9 % sodium chloride, COR-1, Standard therapy for heart failure
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Corimmun GmbH